Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;29(3):435-40.
doi: 10.1089/aid.2012.0234. Epub 2012 Nov 7.

Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons

Affiliations

Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons

Wanda Lakey et al. AIDS Res Hum Retroviruses. 2013 Mar.

Abstract

Data on weight gain and the progression to overweight/obesity in HIV-infected persons during initial combination antiretroviral therapy (cART) are limited, and comparisons to the general population are inconclusive. Weight and body mass index (BMI) changes were studied in HIV-infected adults who remained on initial cART for 12 consecutive months and in an HIV-uninfected cohort receiving care at Duke University Medical Center between 1998 and 2008. Overweight/obesity was defined as BMI ≥25 kg/m(2). Variables were analyzed by Chi-square and Student's t-tests. Ninety-two HIV-infected persons (median age 38.2 years) met inclusion criteria. Weight and BMI increased during 12 months of cART (80.0 to 84.4 kg, p<0.0001; 26.4 to 27.9 kg/m(2), p<0.0001; respectively). Weight gain was greater in HIV-infected females compared to males (8.6 vs. 3.6 kg, p=0.04), in persons treated with protease inhibitor (PI)-based cART compared to non-PI-based cART (9.0 vs. 2.7 kg, p=0.001), and in persons with a pretreatment CD4 count <200 cells/mm(3) compared to ≥200 cells/mm(3) (8.9 vs. 0.3 kg, p<0.0001). Overweight/obesity prevalence increased from 52% to 66% during 12 months of initial cART, a 27% relative increase (p=0.002). HIV-infected persons had a lower prevalence of pretreatment overweight/obesity compared to 94 age-matched control subjects (52% vs. 91%, p<0.001); however, there was no change in weight (92.7 vs. 93.0 kg, p=0.5) or overweight/obesity prevalence (91% to 92%, p>0.9) during 12 months in the control cohort. Management should anticipate excess weight gain during the first year of cART in persons who are female, have a pretreatment CD4 <200 cells/mm(3), or will initiate PI-based cART.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
(A) Body mass index (BMI) categories at baseline prior to treatment and 12 months after initial combination antiretroviral therapy in the HIV-infected cohort. (B) BMI categories at baseline and after 12 months of follow-up in the control cohort. BMI categories (kg/m2): underweight (UW) <18.5, normal 18.50–24.99, overweight (OW) 25.00–29.99, obese (OB) ≥30.00, overweight/obese (OW/OB) ≥25.00.

Similar articles

Cited by

References

    1. Amorosa V. Synnestvedt M. Gross R. Freidman H. MacGregor RR. Gudonis D. Frank I. Tebas P. A tale of 2 epidemics: The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557–561. - PubMed
    1. Crum-Cianflone N. Tejidor R. Medina S. Barahona I. Ganesan A. Obesity among patients with HIV: The latest epidemic. AIDS Patient Care STDs. 2008;22:925–930. - PMC - PubMed
    1. NIH publication no. 98-4083. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; Bethesda, MD: 1998. NHLBI Obesity Education Initiative: Clinical guidelines on the identification, evaluation, treatment of overweight, obesity in adults: The evidence report.
    1. Klein D. Hurley LB. Quesenberry CP. Sidney S. Do protease inhibitors increase the risk of coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471–477. - PubMed
    1. Currier JS. Taylor A. Boyd F. Dezil CM. Kawabata H. Burtcel B. Maa JF. Hodder S. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512. - PubMed

Publication types

Substances